Volume 29, Issue 2 pp. 186-192
RESEARCH REPORT

Physico-chemical stability of Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose with eight common intravenous medications

Rachael Dawson

Rachael Dawson

School of Medicine, University of Nottingham, Nottingham, UK

Search for more papers by this author
Andrew Wignell

Andrew Wignell

School of Pharmacy, University of Nottingham, Nottingham, UK

Paediatric Critical Care Unit, Nottingham Children’s Hospital, Nottingham, UK

Search for more papers by this author
Paul Cooling

Paul Cooling

School of Pharmacy, University of Nottingham, Nottingham, UK

Search for more papers by this author
David Barrett

David Barrett

School of Pharmacy, University of Nottingham, Nottingham, UK

Search for more papers by this author
Harish Vyas

Harish Vyas

School of Medicine, University of Nottingham, Nottingham, UK

Paediatric Critical Care Unit, Nottingham Children’s Hospital, Nottingham, UK

Search for more papers by this author
Patrick Davies

Corresponding Author

Patrick Davies

School of Medicine, University of Nottingham, Nottingham, UK

Paediatric Critical Care Unit, Nottingham Children’s Hospital, Nottingham, UK

Correspondence

Patrick Davies, Paediatric Critical Care Unit, Queen’s Medical Centre, Nottingham Children’s Hospital, Nottingham, UK.

Email: [email protected]

Search for more papers by this author
First published: 25 November 2018
Citations: 4

Funding information

Nottingham University Hospitals Charity kindly donated £2500 (Paediatric Research Fund).

Summary

Background

Plasma-Lyte 148® is a balanced, crystalloid intravenous (IV) fluid which is both calcium-free and isotonic. It prevents the hyperchloremic metabolic acidosis and iatrogenic hyponatremia seen with use of 0.9% sodium chloride and hypotonic solutions, respectively. However, data on compatibility with commonly used drugs are lacking.

Aims

To investigate the stability of Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose with eight commonly used therapeutic agents when compared with 5% glucose and 0.9% sodium chloride as diluents. We aimed to provide vital data which may facilitate the introduction of what appears to be a safer and more economic fluid.

Methods

Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose were mixed with morphine, midazolam, fentanyl, ketamine, clonidine, aminophylline, salbutamol, and furosemide at set concentrations. Comparisons were made to 0.9% sodium chloride and 5% glucose fluid controls. Six repeats of each IV fluid and drug admixture were analyzed through high-performance liquid chromatography at three time points: 0, 2, and 24 hours. A concentration change of <5% was defined as chemically stable. Physical stability was assessed by observation of precipitate formation or color change. pH changes were measured using a Fisherbrand Hydrus 300 pH meter.

Results

Relative to starting concentration, all drugs except midazolam were stable to ±3%. All examined therapeutic agents were chemically stable at 2 and 24 hours relative to control solutions. No precipitate formed in any of the samples. All Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose drug admixtures remained in a safe, peripheral administration pH range of 5-9 and were closer to the pH of blood than standard fluid-drug admixtures.

Conclusion

Morphine, fentanyl, ketamine, salbutamol, aminophylline, and clonidine are stable for 24 hours when mixed with Plasma-Lyte 148® and Plasma-Lyte 148®+5% Glucose for administration at concentrations equivalent to those found at a typical Y-site with maintenance fluid. Furosemide is stable at lower concentrations than those seen at a Y-site, but midazolam displayed instability.

CONFLICT OF INTEREST

The authors report no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.